Cantor Fitzgerald Comments on CG Oncology FY2025 Earnings

CG Oncology, Inc. (NASDAQ:CGON - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for CG Oncology in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will earn ($1.52) per share for the year. The consensus estimate for CG Oncology's current full-year earnings is ($1.31) per share.

A number of other brokerages have also commented on CGON. UBS Group initiated coverage on CG Oncology in a report on Thursday, October 24th. They issued a "buy" rating and a $60.00 price objective on the stock. HC Wainwright reaffirmed a "buy" rating and set a $75.00 price target on shares of CG Oncology in a report on Friday, January 10th. Bank of America restated a "buy" rating and issued a $65.00 price target on shares of CG Oncology in a research note on Tuesday, October 8th. TD Cowen began coverage on shares of CG Oncology in a report on Tuesday, January 7th. They issued a "buy" rating for the company. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $66.00 price objective on shares of CG Oncology in a research note on Friday, December 6th. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $63.88.

CG Oncology Stock Up 1.8 %

Shares of NASDAQ:CGON traded up $0.54 during mid-day trading on Thursday, reaching $30.75. 552,514 shares of the stock were exchanged, compared to its average volume of 732,537. The stock's 50 day simple moving average is $31.05 and its 200-day simple moving average is $34.13. CG Oncology has a one year low of $25.77 and a one year high of $50.23.

CG Oncology (NASDAQ:CGON - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.36) by $0.06. CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.97%. The business had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.30 million.

Insider Activity

In related news, Director Hong Fang Song sold 700,000 shares of CG Oncology stock in a transaction on Monday, December 16th. The shares were sold at an average price of $28.00, for a total transaction of $19,600,000.00. Following the transaction, the director now owns 3,003,931 shares in the company, valued at approximately $84,110,068. The trade was a 18.90 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Leonard E. Post sold 1,000 shares of the business's stock in a transaction on Monday, January 13th. The stock was sold at an average price of $29.66, for a total transaction of $29,660.00. The disclosure for this sale can be found here. Insiders sold 702,000 shares of company stock valued at $19,664,200 over the last three months.

Institutional Trading of CG Oncology

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CGON. State Street Corp lifted its position in shares of CG Oncology by 73.0% in the 3rd quarter. State Street Corp now owns 1,700,653 shares of the company's stock worth $64,166,000 after purchasing an additional 717,722 shares during the period. Point72 Asset Management L.P. increased its position in shares of CG Oncology by 575.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 746,063 shares of the company's stock valued at $28,149,000 after acquiring an additional 635,653 shares during the period. Geode Capital Management LLC raised its stake in shares of CG Oncology by 96.2% in the third quarter. Geode Capital Management LLC now owns 1,078,527 shares of the company's stock worth $40,701,000 after purchasing an additional 528,749 shares during the last quarter. Deerfield Management Company L.P. Series C lifted its stake in CG Oncology by 811.9% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 433,540 shares of the company's stock valued at $13,687,000 after acquiring an additional 386,000 shares during the period. Finally, Wellington Management Group LLP boosted its holdings in CG Oncology by 153.4% in the third quarter. Wellington Management Group LLP now owns 510,219 shares of the company's stock valued at $19,251,000 after purchasing an additional 308,852 shares during the last quarter. 26.56% of the stock is owned by hedge funds and other institutional investors.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.